Company news

Curis, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Curis, Inc. Announces Pricing of $8.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules with Existing Healthcare Focused Institutional Investors

October 16, 2026

Curis, Inc. Announces Pricing of $5.6 Million Public Offering

August 13, 2026

Curis Doses First Five Patients in TakeAim CLL Study

July 30, 2026

Curis Announces Positive Emavusertib Update

July 22, 2026

Curis Consents First Six Patients in TakeAim CLL Study

July 6, 2026

Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split

June 26, 2026

Curis Provides First Quarter 2026 Business Update

May 12, 2026

Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026

May 5, 2026

Curis Provides Fourth Quarter 2025 Business Update

March 19, 2026

Curis to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on March 19, 2026

March 12, 2026

Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

January 9, 2026

Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

January 7, 2026

Curis Provides Updated Data from its Frontline AML Triplet Study

December 9, 2025

Curis to Present at Upcoming 30th Annual SNO Meeting

November 14, 2025

Curis Provides Third Quarter 2025 Business Update

November 6, 2025

Curis to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2025

October 30, 2025

Curis Reports Inducement Grants under NASDAQ Listing Rule 5635(4)

October 6, 2025

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

October 3, 2025

Curis to Present at Upcoming Healthcare Conferences in September

September 2, 2025

Curis Provides Second Quarter 2025 Business Update

August 5, 2025

Curis to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2025

July 29, 2025

Curis Announces $7.0 Million Registered Direct and Concurrent Private Placement

July 2, 2025

Curis Provides First Quarter 2025 Business Update

May 6, 2025

Curis to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2025

April 29, 2025

Curis to Present at Upcoming Healthcare Conference in April

April 2, 2025

Curis Provides Fourth Quarter 2024 Business Update

March 31, 2025

Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025

March 28, 2025

Curis Provides Third Quarter 2024 Business Update

November 13, 2024

Curis Announces $12.1 Million Registered Direct and Concurrent Private Placement

October 28, 2024

Curis Announces the 3rd Annual Symposium on IRAK4 in Cancer

September 22, 2024

Curis Provides Second Quarter 2024 Financial and Operating Update

July 31, 2024

Curis Announces Additional Data from TakeAim Leukemia Study

May 13, 2024

Curis Provides First Quarter 2024 Business Update

May 6, 2024

Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024

April 29, 2024

Curis Provides Fourth Quarter 2023 Business Update

February 7, 2024

Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024

January 31, 2024

Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study

December 11, 2023

Curis Announces Three Presentations at ASH

December 5, 2023

Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma

December 4, 2023

Curis Provides Third Quarter 2023 Business Update

November 1, 2023

Curis to Release Third Quarter 2023 Financial Results and Hold Conference Call on November 2, 2023

October 25, 2023

Curis Announces Date for the 2nd Symposium on IRAK4 in Cancer

September 11, 2023

Curis Provides Second Quarter 2023 Business Update

August 2, 2023

Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023

July 26, 2023

Curis Announces $15.1 Million Registered Direct Offering

July 5, 2023

Curis Provides First Quarter 2023 Business Update

May 3, 2023

Curis Reschedules Fourth Quarter 2022 Business Update and Conference Call

March 7, 2023

Curis to Release Fourth Quarter 2022 Financial Results and Hold Conference Call on March 9, 2023

March 1, 2023

Curis Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS

December 11, 2022

Curis Provides Third Quarter 2022 Business Update

November 8, 2022

Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 55 decks. Every deck is listed under its year.